PolyPid Ltd
PYPD3.510USD
+0.110+3.24%
Horário de mercado （ET）Cotações atrasadas em 15 min
35.77MValor de mercado
PerdaP/L TTM
Mais detalhes de PolyPid Ltd Empresa
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Informações da empresa
Código da empresaPYPD
Nome da EmpresaPolyPid Ltd
Data de listagemJun 26, 2020
CEOMs. Dikla Czaczkes Akselbrad
Número de funcionários57
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 26
Endereço18 Hasivim Street, P.O Box 7126
CidadePETAH TIKVA
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísIsrael
Código postal4917002
Telefone972747195700
Sitehttps://www.polypid.com
Código da empresaPYPD
Data de listagemJun 26, 2020
CEOMs. Dikla Czaczkes Akselbrad
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Yechezkel Barenholz, Ph.D.
Dr. Yechezkel Barenholz, Ph.D.
Independent Director
Independent Director
2.76K
--
Ms. Dikla Czaczkes Akselbrad
Ms. Dikla Czaczkes Akselbrad
Chief Executive Officer, Director
Chief Executive Officer, Director
934.00
+100.00%
Dr. Itzhak Krinsky, Ph.D.
Dr. Itzhak Krinsky, Ph.D.
Independent Director
Independent Director
833.00
--
Mr. Jacob Harel
Mr. Jacob Harel
Independent Chairman of the Board
Independent Chairman of the Board
467.00
--
Mr. Ori Warshavsky
Mr. Ori Warshavsky
Chief Operating Officer - US
Chief Operating Officer - US
267.00
--
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
--
--
Dr. Shaul Mukhtar, Ph.D.
Dr. Shaul Mukhtar, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Ms. Dalit Hazan
Ms. Dalit Hazan
Senior Vice President - Research and Development and Regulatory Affairs
Senior Vice President - Research and Development and Regulatory Affairs
--
--
Dr. Noam Emanuel, Ph.D.
Dr. Noam Emanuel, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Robert Burton (Bob) Stein, M.D., Ph.D.
Dr. Robert Burton (Bob) Stein, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Yechezkel Barenholz, Ph.D.
Dr. Yechezkel Barenholz, Ph.D.
Independent Director
Independent Director
2.76K
--
Ms. Dikla Czaczkes Akselbrad
Ms. Dikla Czaczkes Akselbrad
Chief Executive Officer, Director
Chief Executive Officer, Director
934.00
+100.00%
Dr. Itzhak Krinsky, Ph.D.
Dr. Itzhak Krinsky, Ph.D.
Independent Director
Independent Director
833.00
--
Mr. Jacob Harel
Mr. Jacob Harel
Independent Chairman of the Board
Independent Chairman of the Board
467.00
--
Mr. Ori Warshavsky
Mr. Ori Warshavsky
Chief Operating Officer - US
Chief Operating Officer - US
267.00
--
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Aurum Ventures M.K.I.
19.88%
Centaurus Investments Limited
10.87%
Rosalind Advisors, Inc.
9.99%
Nir (Yehuda)
6.02%
Hewlett Fund, L.P.
5.77%
Other
47.47%
Investidores
Investidores
Proporção
Aurum Ventures M.K.I.
19.88%
Centaurus Investments Limited
10.87%
Rosalind Advisors, Inc.
9.99%
Nir (Yehuda)
6.02%
Hewlett Fund, L.P.
5.77%
Other
47.47%
Tipos de investidores
Investidores
Proporção
Venture Capital
19.88%
Hedge Fund
19.57%
Holding Company
10.87%
Individual Investor
9.02%
Corporation
5.77%
Investment Advisor/Hedge Fund
4.75%
Private Equity
4.54%
Investment Advisor
0.28%
Research Firm
0.02%
Other
25.31%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
41
7.61M
74.69%
+1.40M
2025Q1
42
7.66M
75.16%
+942.60K
2024Q4
44
5.48M
65.20%
+1.87M
2024Q3
50
4.47M
69.98%
+1.49M
2024Q2
58
3.43M
73.51%
+1.59M
2024Q1
59
3.33M
71.29%
+2.56M
2023Q4
54
443.78K
34.10%
+80.67K
2023Q3
57
479.04K
37.01%
+97.48K
2023Q2
57
472.86K
36.65%
+91.51K
2023Q1
59
332.36K
28.62%
+89.40K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Aurum Ventures M.K.I.
2.03M
19.88%
+11.34K
+0.56%
Feb 26, 2025
Centaurus Investments Limited
1.11M
10.87%
+475.10K
+75.12%
Dec 31, 2024
Rosalind Advisors, Inc.
1.02M
9.99%
--
--
Mar 31, 2025
Nir (Yehuda)
613.91K
6.02%
+62.60K
+11.36%
Mar 31, 2025
Hewlett Fund, L.P.
587.92K
5.77%
+338.44K
+135.66%
Feb 26, 2025
Triple Gate Capital, LP
465.84K
4.57%
+465.84K
--
Feb 26, 2025
AIGH Capital Management, LLC.
510.95K
5.01%
-507.07K
-49.81%
Mar 31, 2025
Worth Venture Partners, LLC
429.43K
4.21%
+153.81K
+55.80%
Mar 31, 2025
Lukach (Aharon)
299.55K
2.94%
-5.64K
-1.85%
Mar 31, 2025
Dafna Capital Management, LLC
291.27K
2.86%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
Data
Tipo
Proporção
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
Aug 30, 2023
Merger
30<1
